Cell Therapy News

Cell Therapy News is an online resource dedicated to sharing the latest cell therapy, gene therapy, and regenerative medicine research.

Penn Medicine’s Carl June to Receive 2024 Breakthrough Prize in Life Sciences

[Penn Today] In the decades since June began his CAR T cell research, the field has grown exponentially, with hundreds of CAR T cell clinical trials now in progress worldwide.

Axicabtagene Ciloleucel in Large B Cell Lymphoma Ineligible for Autologous Stem Cell Transplantation: The Phase II Alycante Trial

[Nature Medicine] Investigators conducted a Phase II study (ALYCANTE) to assess the efficacy and safety of a single axi-cel infusion as a second-line therapy in patients with high-risk relapsed/refractory (R/R) large B cell lymphoma deemed ineligible for ASCT but eligible for CAR-T cell therapy.

In Vitro Vascular Differentiation System Efficiently Produces Natural Killer Cells for Cancer Immunotherapies

[Oncoimmunology] Human pluripotent stem cells were differentiated into hematopoietic progenitor cells (HPCs) and Natural Killer cells using a novel organoid system. HPC engraftment potential was assessed using NSG mice.

One-Step Cell Biomanufacturing Platform: Porous Gelatin Microcarrier Beads Promote Human Embryonic Stem Cell-Derived Midbrain Dopaminergic Progenitor Cell Differentiation In Vitro and Survival after Transplantation...

[Neural Regeneration Research] Scientists developed a one-step biomanufacturing platform that uses small-aperture gelatin microcarriers to produce beads carrying midbrain dopaminergic progenitor cells.

3D-Printed Polycaprolactone Scaffolds Coated with Beta Tricalcium Phosphate for Bone Regeneration

[Journal Of The Formosan Medical Association] Investigators used the fused deposition modeling technique with the 3D printing technique to fabricate the thermoplastic polymer and composite scaffolds. MG-63 cells were injected and attached to the mesh-manufactured polycaprolactone scaffolds.

F77 Antigen Is a Promising Target for Adoptive T Cell Therapy of Prostate Cancer

[Biochemical And Biophysical Research Communications] Scientists entailed the generation and evaluation of a second-generation CAR against a carbohydrate antigen on malignant prostate cancer cells.

In Vitro Spermatogenesis in Artificial Testis: Current Knowledge and Clinical Implications for Male Infertility

[Cell And Tissue Research] The rate of progression and breakthrough in the area of in vitro spermatogenesis is lower than that of spermatogonial stem cell transplantation, but newer methods are being developed.

Medigene AG Announces Lead Selection for MDG2011 Representing the First TCR-T Therapy of its KRAS Library

[Medigene AG] Medigene AG announced that it has selected its lead candidate for MDG2011, a T cell receptor engineered T cell (TCR-T) therapy targeting KRAS G12V with HLA-A*11 and being developed in combination with the Company’s PD1-41BB costimulatory switch protein technology.

Targeted Glycan Degradation Potentiates Cellular Immunotherapy for Solid Tumors

[Proceedings Of The National Academy Of Sciences Of The United States Of America] The combination of cancer cell desialylation and induced pluripotent stem cell–derived chimeric antigen receptor–macrophage adoptive cellular therapy exerted a dramatic therapeutic effect on solid tumors and significantly prolonged the survival of tumor-bearing mice.

Stressed Target Cancer Cells Drive Nongenetic Reprogramming of CAR T Cells and Solid Tumor Microenvironment

[Nature Communications] The authors described a broadly applicable nongenetic approach that simultaneously addresses the multiple challenges of CAR T as a therapy for solid tumors.

Small RNA Sequencing Analysis of Exosomes Derived from Umbilical Plasma in IUGR Lambs

[Communications Biology] Researchers established a heat-stressed Hu sheep model during mid-late gestation and selected intrauterine growth retardation and normal lambs for analysis. Exosomes from umbilical plasma were separated and small RNA sequencing is used to identify differentially expressed miRNAs.

Dominant Negative TGFβ Receptor II and Truncated TIM3 Enhance the Antitumor Efficacy of CAR-T-Cell Therapy in Prostate Cancer

[International Immunopharmacology] Researchers attempted to improve the tumor killing capability of prostate-specific membrane antigen-chimeric antigen receptor T (CAR-T) cells by targeting T cell immunoglobulin and mucin domain 3 (TIM3) and transforming growth factor beta (TGFβ) receptor II simultaneously.

Published since 2002, Cell Therapy News is our longest running online publication. Our editorial team curates the top publications, reviews, and news on in vivo gene therapy, cell therapy, and immunotherapy research. With over 15,000 subscribers and followers across our website, email newsletter, and Twitter feed, we are proud to facilitate the communication of cutting-edge cell therapy innovations.